CLEC5a-directed bispecific antibody for effective cellular phagocytosis
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB). Here, we describe a bispecific antibody approach that harnesses phag...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a4637a431cdc4e5c801dd6e32b9072f3 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Vivekananda Kedage |e author |
| 700 | 1 | 0 | |a Diego Ellerman |e author |
| 700 | 1 | 0 | |a Mingjian Fei |e author |
| 700 | 1 | 0 | |a Wei-Ching Liang |e author |
| 700 | 1 | 0 | |a Gu Zhang |e author |
| 700 | 1 | 0 | |a Eric Cheng |e author |
| 700 | 1 | 0 | |a Juan Zhang |e author |
| 700 | 1 | 0 | |a Yongmei Chen |e author |
| 700 | 1 | 0 | |a Haochu Huang |e author |
| 700 | 1 | 0 | |a Wyne P. Lee |e author |
| 700 | 1 | 0 | |a Yan Wu |e author |
| 700 | 1 | 0 | |a Minhong Yan |e author |
| 245 | 0 | 0 | |a CLEC5a-directed bispecific antibody for effective cellular phagocytosis |
| 260 | |b Taylor & Francis Group, |c 2022-12-01T00:00:00Z. | ||
| 500 | |a 10.1080/19420862.2022.2040083 | ||
| 500 | |a 1942-0870 | ||
| 500 | |a 1942-0862 | ||
| 520 | |a While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB). Here, we describe a bispecific antibody approach that harnesses phagocytic receptor CLEC5A (C-type Lectin Domain Containing 5A) to drive Fcγ receptor-independent phagocytosis, potentially circumventing the negative impact of FcγRIIB. First, we established the effectiveness of such an approach by constructing bispecific antibodies that simultaneously target CLEC5A and live B cells. Furthermore, we demonstrated its in vivo application for regulatory T cell depletion and subsequent tumor regression. | ||
| 546 | |a EN | ||
| 690 | |a Phagocytosis | ||
| 690 | |a bispecific antibody | ||
| 690 | |a CLEC5A | ||
| 690 | |a Fcγ receptor | ||
| 690 | |a treg | ||
| 690 | |a tumor-associated macrophage | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n mAbs, Vol 14, Iss 1 (2022) | |
| 787 | 0 | |n https://www.tandfonline.com/doi/10.1080/19420862.2022.2040083 | |
| 787 | 0 | |n https://doaj.org/toc/1942-0862 | |
| 787 | 0 | |n https://doaj.org/toc/1942-0870 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a4637a431cdc4e5c801dd6e32b9072f3 |z Connect to this object online. |